A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. - Noguchi E; Yamanaka T; Mukai H; Yamamoto N; Chung CF; Lu YS; Chang DY; Sohn J; Kim GM; Lee KH; Lee SC; Iwasa T; et al. (NPJ breast cancer, 2024)